Cell Death and Disease (Feb 2022)

Immune-responsive gene 1/itaconate activates nuclear factor erythroid 2-related factor 2 in microglia to protect against spinal cord injury in mice

  • Libin Ni,
  • Jian Xiao,
  • Di Zhang,
  • Zhenxuan Shao,
  • Chongan Huang,
  • Sheng Wang,
  • Yaosen Wu,
  • Naifeng Tian,
  • Liaojun Sun,
  • Aimin Wu,
  • Yifei Zhou,
  • Xiangyang Wang,
  • Xiaolei Zhang

DOI
https://doi.org/10.1038/s41419-022-04592-4
Journal volume & issue
Vol. 13, no. 2
pp. 1 – 16

Abstract

Read online

Abstract The pathophysiology of spinal cord injury (SCI) involves primary injury and secondary injury. Secondary injury is a major target for SCI therapy, whereas microglia play an important role in secondary injury. The immunoresponsive gene 1 (Irg-1) has been recorded as one of the most significantly upregulated genes in SCI tissues in gene chip data; however, its role in SCI remains unclear. This study aims to illustrate the role of Irg-1 as well as its regulated metabolite itaconate in SCI. It was demonstrated that the expression of Irg-1 was increased in spinal cord tissues in mice as well as in microglia stimulated by lipopolysaccharides (LPS). It was also shown that overexpression of Irg-1 may suppress LPS-induced inflammation in microglia, while these protective effects were attenuated by Nrf2 silencing. In vivo, overexpression of Irg-1 was shown to suppress neuroinflammation and improve motor function recovery. Furthermore, treatment of microglia with itaconate demonstrated similar inflammation suppressive effects as Irg-1 overexpression in vitro and improved motor function recovery in vivo. In conclusion, the current study shows that Irg-1 and itaconate are involved in the recovery process of SCI, either Irg-1 overexpression or itaconate treatment may provide a promising strategy for the treatment of SCI.